Cardiovascular Therapeutics and Strategies

Mucke HAM: Small-molecule endothelin receptor antagonists: a review of patenting activity across therapeutic areas. IDrugs 12(6): 366-75 (2009) PubMed link

Mucke HAM: Sitaxentan for the Oral Treatment of Pulmonary Arterial Hypertension: Benefits from Endothelin Receptor Subtype Selectivity? Clinical Medicine: Therapeutics 1: 111-121 (2009)  Download

Mucke HAM: Pulmonary hypertension: on the way to a manageable disease. Curr Opin Investig Drugs 9(9): 957-62 (2008) PubMed link

Mucke HAM: Cardiovascular developments: patent highlights July to December 2006. Curr Opin Investig Drugs 8(3): 193-200 (2007) PubMed link

Mucke HAM: Cardiovascular and renal developments: patent highlights January to June 2006. Curr Opin Investig Drugs 7(9): 792-8 (2006) PubMed link

Mucke HAM: Genomics-based cardiovascular drug development: the challenges are just beginning. Curr Opin Investig Drugs 7(3): 203-5 (2006) PubMed link

Mucke HAM: The failing heart as a drug target: are we finally seeing progress? Curr Opin Investig Drugs 6(9): 870-3 (2005) PubMed link

Mucke HAM: Renal therapeutics: patent highlights January to June 2003. Curr Opin Investig Drugs 4(9): 1048-52 (2003) PubMed link